🇺🇸 FDA
Pipeline program

REGN4461 - Mibavademab

R4461-MOB-2471

Phase 3 small_molecule active

Quick answer

REGN4461 - Mibavademab for Monogenic obesity is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Monogenic obesity
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials